MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.65
+0.69
+3.64%
After Hours: 19.65 0 0.00% 16:00 05/27 EDT
OPEN
18.93
PREV CLOSE
18.96
HIGH
19.76
LOW
18.24
VOLUME
234.73K
TURNOVER
0
52 WEEK HIGH
37.89
52 WEEK LOW
18.24
MARKET CAP
553.86M
P/E (TTM)
-7.1491
1D
5D
1M
3M
1Y
5Y
Short Volatility Alert: AnaptysBio, Inc.
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish.
Benzinga · 2d ago
AnaptysBio's Return On Capital Employed Insights
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.
Benzinga · 4d ago
Downgrade: Here's How Analysts See AnaptysBio, Inc. (NASDAQ:ANAB) Performing In The Near Term
One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...
Simply Wall St. · 05/10 10:09
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:55
AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M
AnaptysBio press release (NASDAQ:ANAB): Q1 GAAP EPS of -$1.31 misses by $0.32. Revenue of $0.97M (-91.4% Y/Y) misses by $4.08M. Shares -1.6% AH. Top-line data from the ongoing imsidolimab (anti-IL-36R
Seekingalpha · 05/04 21:41
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 04/28 12:52
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
Benzinga · 04/28 12:48
BRIEF-Anaptysbio Announces Positive Anb032 (Anti-Btla Agonist) Top-Line Phase 1 Data And Provides Pipeline Updates
reuters.com · 04/27 20:34
More
No Data
Learn about the latest financial forecast of ANAB. Analyze the recent business situations of Anaptysbio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
28.57%Buy
57.14%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average ANAB stock price target is 38.40 with a high estimate of 50.00 and a low estimate of 29.00.
High50.00
Average38.40
Low29.00
Current 19.65
EPS
Actual
Estimate
-0.410.501.402.31
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 211
Institutional Holdings: 45.12M
% Owned: 160.09%
Shares Outstanding: 28.19M
TypeInstitutionsShares
Increased
33
1.97M
New
17
2.06M
Decreased
51
868.32K
Sold Out
21
1.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
James Topper
President/Chief Executive Officer/Director
Daniel Faga
Chief Financial Officer
Dennis Mulroy
Chief Operating Officer/General Counsel
Eric Loumeau
Other
Paul Lizzul
Lead Director/Independent Director
Hollings Renton
Independent Director
Dennis Fenton
Independent Director
Laura Hamill
Independent Director
Magda Marquet
Independent Director
Oleg Nodelman
Independent Director
John Schmid
Independent Director
J. Anthony Ware
No Data
No Data
About ANAB
AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.